|
T9928 |
Ranibizumab
|
|
VEGFR
|
|
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and n... |
|
T13157 |
TG 100801
|
TG100801,TG 100572 |
VEGFR
,
Src
|
|
TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD). |
|
T2706 |
Palomid 529
|
P529,SG 00529 |
Apoptosis
,
mTOR
|
|
Palomid 529 (SG 00529) has been used in trials studying the treatment of Age-Related Macular Degeneration. |
|
T7493 |
AG-13958
|
AG-013958 |
VEGFR
|
|
AG-13958 (AG-013958) (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration. |
|
T28273L |
OT-551 HCl
|
OT-551 HCl（627085-11-4 Free base） |
NF-κB
|
|
OT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA). |
|
T77600 |
Methyl-4-oxoretinoate
|
|
Apoptosis
|
|
Methyl-4-oxoretinoate is a synthetic retinoid compound with anticancer compounds that can induce differentiation and apoptosis in cancer cells.Methyl-4-oxoretinoate is used in the treatment of acne, psoriasis, and other ... |
|
T28273 |
OT-551
|
CPC 551,OT 551,CPC551,CPC-551 |
|
|
OT-551, a NF-κB inhibitor, is used potentially for the treatment of cataracts and age-related macular degeneration. |
|
T27670 |
JNJ-26076713
|
JNJ26076713 |
|
|
JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy. |
|
TP1390 |
CEP dipeptide 1
|
|
|
|
CEP dipeptide 1, a potent angiogenic compound, exhibits robust activity in promoting angiogenesis. This compound is specifically implicated in the pathogenesis of age-related macular degeneration (AMD). |
|
T39706 |
Pegaptanib sodium
|
|
|
|
Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD). |
|
T9695L |
POT-4 acetate
|
POT-4 acetate (934461-40-2 free base) |
Complement System
|
|
POT-4 acetate inhibits Complement C3 activation. POT-4 acetate can be used for studies about age-related macular degeneration. |
|
T71988 |
Moxaverine hydrochloride
|
|
|
|
Moxaverine hydrochloride is a derivative of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related mac... |
|
T36620 |
ALK4290
|
ALK4290 |
|
|
ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsoni... |
|
T13157L |
TG 100801 Hydrochloride
|
|
VEGFR
|
|
TG 100801 Hydrochloride is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PD... |
|
TP1464 |
Risuteganib hydrochloride
|
|
|
|
Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order ... |
|
T77016 |
Galegenimab
|
|
|
|
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an antibody fragment targeting High-temperature requirement A1 (HTRA1), is utilized in the research of age-related macular degeneration (AMD) [1]. |
|
T76887 |
Rinucumab
|
|
|
|
Rinucumab (REGN 2176), a monoclonal antibody that acts as a PDGF inhibitor, holds potential for researching neovascular age-related macular degeneration [1]. |
|
T76210 |
POT-4 TFA
|
|
|
|
POT-4 TFA (AL-78898A TFA), a derivative of Compstatin, effectively inhibits the activation of complement factor C3. This compound is utilized in research related to age-related macular degeneration [1] [2]. |
|
T74867 |
UBX1325
|
|
|
|
UBX1325, a Bcl-xL inhibitor, enhances apoptosis in senescent cells, serving as an effective anti-aging agent. It holds potential for age-related eye disease research, including diabetic macular oedema (DME), age-related ... |
|
T75156L |
Bevasiranib sodium
|
|
|
|
Bevasiranib sodium, an siRNA compound, targets and silences the genes responsible for producing vascular endothelial growth factor (VEGF). The suppression of VEGF, a critical factor in the development of choroidal neo-va... |
|
T75156 |
Bevasiranib
|
|
|
|
Bevasiranib, a siRNA, is specifically engineered to suppress the expression of genes responsible for the production of vascular endothelial growth factor (VEGF), a critical factor in the development of choroidal neo-vasc... |
|
T76987 |
Tarcocimab
|
|
|
|
Tarcocimab (OG1953), a humanized IgG1-type anti-VEGFA monoclonal antibody, is utilized in research targeting conditions such as retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD). |
|
T69452 |
AG-13958 monohydrochloride
|
|
|
|
AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic bl... |
|
T79010 |
Lp-PLA2-IN-12
|
|
Phospholipase
|
|
Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is utilized in researching neurodegenerative diseases including Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular conditions... |
|
T74551 |
Avacincaptad pegol sodium
|
|
|
|
Avacincaptad pegol (ARC1905), an anti-C5 RNA aptamer, prevents the cleavage of complement factor 5 (C5) into fragments C5a and C5b. It is currently under investigation for the treatment of age-related macular degeneratio... |
|
T76814 |
Lampalizumab
|
|
|
|
Lampalizumab (RG 7417), a humanized monoclonal antibody, selectively inhibits complement Factor D in the alternative complement pathway by binding to an exosite and sterically hindering Factor B's access to the active si... |
|
T74552 |
Non-PEGylated/naked ARC1905
|
|
|
|
ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched ... |
|
T79074 |
Lp-PLA2-IN-14
|
|
Phospholipase
|
|
Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4. This compound is applicable in research pertaining to neurodegenerative disorders, including Alzheime... |
|
T63192 |
Lp-PLA2-IN-10
|
|
|
|
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as platelet-activating factor acetylhydrolase (PAF-AH). This enzyme plays a role in the hydrolysis of lipoprotein l... |
